Chinook Therapeutics
KDNY

From March 31, 2023 to June 30, 2023 Issuance of common stock upon exercise of stock options, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units

From December 31, 2022 to March 31, 2023 Issuance of common stock under the at-the-market sales agreement, net of issuance costs Issuance of common stock upon exercise of stock options and vesting of restricted stock units

From December 31, 2021 to December 31, 2022 Issuance of common stock upon exercise of stock options and warrants, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units Issuance of common stock under the at-the-market sales agreement, net of issuance costs Issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs

From June 30, 2022 to September 30, 2022 Issuance of common stock upon exercise of stock options and vesting of restricted stock units Issuance of common stock under the at-the-market sales agreement,net of offering costs

From March 31, 2022 to June 30, 2022 Issuance of common stock upon exercise of stock options, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units Issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs

1.Common stock offered by 6,428,572 shares. 2.The number of shares of common stock to be outstanding after this offering is based on 55,116,613 shares of common stock outstanding as of March 31, 2022.

From December 31, 2021 to March 31, 2022 Issuance of common stock upon exercise of stock options and vesting of restricted stock units

From December 31, 2020 to December 31, 2021 Issuance of common stock upon exercise of stock options and warrants, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units Issuance of common stock under the at-the-market sales agreement, net of issuance costs Issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs

1.Common stock offered 7,828,572 shares. 2.The number of shares of common stock to be outstanding after this offering is based on 44,830,005 shares of common stock outstanding as of September 30, 2021.

From June 30, 2021 to September 30, 2021 Issuance of common stock upon exercise of stock options and vesting of restricted stock units

From March 31, 2021 to June 30, 2021 Issuance of common stock upon exercise of stock options and warrants, issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units Issuance of common stock under the at-the-market sales agreement, net of offering costs

from December 31, 2020 to March 31, 2021 Issuance of common stock upon exercise of stock options and warrants

from December 31, 2019 to December 31, 2020 Issuance of Series A redeemable convertible preferred stock, net of issuance cost of $21 Conversion of redeemable convertible preferred stock to common stock Issuance of common stock upon exercise of stock options Vesting of restricted stock units Issuance of common stock under Employee Stock Purchase Plan Repurchase of unvested restricted stock awards Issuance of common stock pursuant to subscription agreements prior to Merger Aduro outstanding common stock assumed as a result of the Merger Issuance of common stock for financial advisory services in connection with the Merger

a 1-5 shares split

From March 31, 2020 to June 30, 2020 Issuance of common stock upon exercise of stock options Issuance of common stock under Employee Stock Purchase Plan Release of restricted stock units

From December 31, 2019 to March 31, 2020 Issuance of common stock upon exercise of stock options Release of restricted stock units

from December 31, 2018 to December 31, 2019 Issuance of common stock upon exercise of stock options Release of restricted stock units Issuance of common stock under Employee Stock Purchase Plan

from June 30, 2019 to September 30, 2019 Issuance of common stock upon exercise of stock options Release of restricted stock units

from March 31, 2019 to June 30, 2019 Issuance of common stock upon exercise of stock options Issuance of common stock under Employee Stock Purchase Plan Release of restricted stock units

from December 31, 2018 to March 31, 2019 Issuance of common stock upon exercise of stock options Release of restricted stock units

from December 31, 2017 to December 31, 2018 Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of warrants Issuance of common stock under Employee Stock Purchase Plan Release of restricted stock units

from December 31, 2016 to December 31, 2017 Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of warrants Issuance of common stock under Employee Stock Purchase Plan Issuance of common stock upon at the market offering Release of restricted stock units

from December 31, 2015 to December 31, 2016 Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of warrants Issuance of common stock under Employee Stock Purchase Plan Issuance of common stock upon at the market offering

From December 31, 2014 to December 31, 2015 Issuance of Series E convertible preferred stock for cash, net of $8 of issuance costs Issuance of convertible preferred stock upon exercise of preferred stock warrants Conversion of convertible preferred stock to common stock Issuance of common stock in initial public offering Issuance of common stock in private placement Issuance of common stock upon exercise of stock options and grants Issuance of common stock upon exercise of warrants Issuance of common stock in business acquisition Issuance of common stock under Employee Stock Purchase Plan On April 1, 2015, the Company effected a 0.72-for-1 reverse split of its common stock

On April 1, 2015, the Company effected a 0.72-for-1 reverse split of its common stock. Upon the effectiveness of the reverse stock split, (i) every 1 share of outstanding common stock was combined into 0.72 of a share of common stock, (ii) the number of shares of common stock for which each outstanding option or warrant to purchase common stock is exercisable was proportionally decreased on a 0.72-for-1 basis, (iii) the exercise price of each outstanding option or warrant to purchase common stock was proportionately increased on a 0.72-for-1 basis, and (iv) the conversion ratio for each share of preferred stock which was convertible into the Company’s common stock was proportionately reduced on a 0.72-for-1 basis. All of the outstanding common stock share numbers, warrants to purchase common stock, common stock share prices, common stock exercise prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 0.72-for-1 reverse stock split for all periods presented. The par value per share, authorized number of shares of common stock, preferred stock and preferred stock warrants were not adjusted as a result of the reverse stock split.

1. the automatic conversion of all outstanding shares of our preferred stock at December 31, 2014 into an aggregate of 50,117,919 shares of common stock upon the closing of this offering;

From January 1, 2015 to March 31, 2015 Issuance of Series E convertible preferred stock for cash, net of issuance costs Issuance of preferred stock upon exercise of preferred stock warrants Issuance of common stock upon exercise of stock options

From December 31, 2013 to December 31, 2014 Issuance of Series C convertible preferred stock for cash, net of $262 of issuance costs Issuance of Series C convertible preferred stock upon conversion of convertible promissory notes Issuance of Series B convertible preferred stock upon conversion of Series B convertible promissory notes Issuance of Series D convertible preferred stock for cash, net of $2,470 of issuance costs Issuance of common stock upon exercise of stock options